TrialModern rheumatology2015

Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis.

Tsutomu Takeuchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.